VR Logo

SAB Biotherapeutics Inc. (SABS) download report

Healthcare | Biotechnology & Pharma Research

SAB Biotherapeutics Inc. (SABS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Get the Stocks!

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.

IPO Date: 09-Feb-2021

Exec. Chairman: Mr. Samuel J. Reich

Co-Founder, Pres, CEO & Director: Dr. Eddie Joe Sullivan Ph.D.

Listing: NASDAQ: SABS

Country: United States

Headquarters: Sioux Falls, SD

Website: https://www.sabbiotherapeutics.com

Key Facts

Market cap: $60.61 Mln

Revenue (TTM): $72.68 Mln

Earnings (TTM): $-11.66 Mln

Cash: $22.41 Mln

Total Debt: $6.41 Mln

Insider's Holding: 38.08%

Liquidity: Low

52 Week range: $1.11 - 12.90

Shares outstanding: 42,987,600

Stock Performance

Time Period SAB Biotherapeutics (SABS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-82.20-8.47-19.22
1 month-29.80-2.85-9.34
3 months-33.81-7.98-14.58
1 Year-86.021.46-17.64
3 Years--10.625.91
5 Years--11.565.64
10 Years--11.8310.10
As on 29-Jun-2022 *As on 30-Jun-2022
AMCs: